Evidence map›Paper›PMID 36050669›Full record

ArticleBMC public health2022

The prevalence of insomnia in different COVID-19 policy phases: Longitudinal evidence from ITA.LI - Italian Lives.

Egidio Riva, Marco Terraneo, Mario Lucchini, Tiziano Gerosa

Open access · goldAbstract read
In one paragraph

Article in BMC public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Prevalence and associations of insomnia after COVID-19 infection.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Egidio RivaDipartimento Di Sociologia E Ricerca Sociale, Università degli Studi di Milano - Bicocca, Via Bicocca degli Arcimboldi, 8, 20126, Milano, Italy. egidio.riva@unimib.it.
Marco TerraneoDipartimento Di Sociologia E Ricerca Sociale, Università degli Studi di Milano - Bicocca, Via Bicocca degli Arcimboldi, 8, 20126, Milano, Italy.
Mario LucchiniDipartimento Di Sociologia E Ricerca Sociale, Università degli Studi di Milano - Bicocca, Via Bicocca degli Arcimboldi, 8, 20126, Milano, Italy.
Tiziano GerosaUniversity of Applied Sciences and Arts of Southern Switzerland, Institute of Applied Sustainability to the Built Environment, Via Flora Ruchat-Roncati, 15, CH-6850, Mendrisio, Switzerland.
University of Milano-Bicocca · ITUniversity of Applied Sciences and Arts of Southern Switzerland · CH

Funding

The economic and social impact of pandemic mitigation policies: A cross-country analysis of macro eventsR01AG071649 · NIA · OHIO STATE UNIVERSITY · PI LILLARD, DEAN R · 2021 to 2025
$4.8M
NIA NIH HHS R01 AG071649
6 · The paper itself

Abstract

backgroundThis study investigated changes in the prevalence of insomnia in Italy during COVID-19, starting from the first lockdown period (8 March 2020). We hypothesized that lockdown precipitated increased prevalence of insomnia symptoms relative to the pre-pandemic period; b) the gradual relaxation of containment measures - post-lockdown period (Phase 2 and Phase 3) - reduced insomnia severity, leading to a relative recovery of pre-pandemic levels; and c) we tested age-related heterogeneity in sleep responses, with an expected higher increase in insomnia in younger and middle-age groups.

methodsAnalyses drew on a subsample (N = 883) of respondents to ITA.LI - Italian Lives, a recently established panel study on a probability sample of individuals aged 16 + living in Italy. To estimate patterns of change in insomnia, we first fitted a random-effects ordered logistic model on the whole sample. We then added an interaction term between policy phases and the respondent age to test whether the relationship between insomnia and policy phases differed across age groups. Analyses accounted for survey non-response weights.

resultsThe fraction of respondents reporting moderate ("somewhat" + 0.159, S.E. 0.017) or severe ("very much" + 0.142, S.E. 0.030) sleep disturbances significantly increased during Phase 1. The prevalence of insomnia followed an inverted U-shaped curve across policy phases, with further increases from baseline levels ("somewhat" + 0.168, S.E. 0.015; "very much" + 0.187, S.E. 0.030) during Phase 2, followed by a relative reduction in Phase 3, although it remained significantly higher than in the pre-pandemic period ("somewhat", + 0.084, S.E. 0.016; "very much", + 0.045, S.E. 0.010). There were significant age-related differences in insomnia patterns, as the discrete change from pre-pandemic levels in the probability of not suffering from insomnia was negative and significant for the younger age group (- 0.269, S.E. 0.060) and for respondents aged 35-54 (- 0.163, S.E. 0.039).

conclusionThere is reason to believe that the emergency policy response to the COVID-19 crisis may have had unintended and possibly scarring effects in terms of increased prevalence of insomnia. The hardest hit were young adults and, to a lesser extent, the middle-aged; however, older respondents (55 +) remained resilient, and their insomnia trajectory bounced back to pre-pandemic levels.

Indexed as

COVID-19Sleep Initiation and Maintenance DisordersCommunicable Disease ControlHumansItalyMiddle AgedPolicyPrevalenceSARS-CoV-2Young AdultContainment policiesItalyPandemicPanel studySleep disturbanceTrajectories

Identifiers

PMID36050669
PMCPMC9434520
OpenAlexW4294085541

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.